RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON,N.J.,March 10,2025--RiboX Therapeutics Ltd. (RiboX),a pioneering biopharmaceutical company,focused on discovering and developing fully engineered circular RNA therapeutics,todayannouncedthat